Changeflow GovPing Healthcare & Life Sciences Patent Application for Novel Crystalline Form o...
Routine Notice Added Draft

Patent Application for Novel Crystalline Form of Amine Compound

Email

Summary

The USPTO has published a patent application (US20260085071A1) for novel crystalline forms of an amine compound, 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine. The application also discloses pharmaceutical compositions and the use of these forms for treating diseases such as atopic dermatitis and urticaria.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application from the USPTO detailing novel crystalline forms of a specific amine compound, identified as 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine. The application, filed on September 29, 2023, and published as US20260085071A1, includes claims for pharmaceutical compositions containing these crystalline forms and their use in treating various dermatological conditions, including atopic dermatitis, itch, pruritus, and urticaria.

While this is a patent application and not a regulatory rule, it signifies potential new intellectual property in the pharmaceutical space. Companies involved in drug development, particularly for dermatological conditions, should be aware of this filing as it may impact future research, development, and market exclusivity for similar compounds. No immediate compliance actions are required for entities outside of those directly involved in the patent process or those whose existing intellectual property might be affected.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

NOVEL CRYSTALLINE FORM OF 1-(8-BROMOPYRIDO[2,3- E][1,2,4]TRIAZOLO[4,3-A]PYRAZIN-4-YL)-NMETHYLAZETIDIN- 3-AMINE

Application US20260085071A1 Kind: A1 Mar 26, 2026

Inventors

Suha PARK, Seiho CHIN, Sumin LEE

Abstract

Novel crystalline forms of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel polymorph for the treatment of diseases, such as atopic dermatitis (AD), itch, pruritus and various forms of urticaria for example chronic idiopathic urticaria subtypes.

CPC Classifications

C07D 471/14 A61K 31/4985

Filing Date

2023-09-29

Application No.

19110267

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260085071A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Patent Filing
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property Drug Development

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!